{"id":2009,"date":"2017-08-23T08:00:31","date_gmt":"2017-08-23T08:00:31","guid":{"rendered":"https:\/\/d.ptpl.dev\/acarix\/acarix-presents-new-frontline-cad-test-at-european-society-of-cardiology-congress-barcelona-august-26-30\/"},"modified":"2024-08-06T12:25:37","modified_gmt":"2024-08-06T12:25:37","slug":"acarix-presents-new-frontline-cad-test-at-european-society-of-cardiology-congress-barcelona-august-26-30","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/acarix-presents-new-frontline-cad-test-at-european-society-of-cardiology-congress-barcelona-august-26-30\/","title":{"rendered":"Acarix presents new frontline CAD test at European Society of Cardiology Congress, Barcelona, August 26-30."},"content":{"rendered":"
<\/div>\n

Press release
Malm\u00f6, August 23, 2017<\/p>\n

Acarix presents new frontline CAD test at European Society of Cardiology Congress, Barcelona, August 26-30.<\/strong><\/p>\n

Advanced acoustic technology detects partial obstruction of coronary arterial flow<\/em><\/strong><\/p>\n

One of the highlights of the Emerging Technology Showcase Area at the European Society of Cardiology Congress in Barcelona, will be Swedish\/Danish Acarix AB's (publ) ("Acarix") CADScor\u00aeSystem, an advanced, easy to use, frontline test to rule out Coronary Artery Disease (CAD) with high accuracy. \u00a0Initial study results released earlier this year show that the Danish Design Award winning CADScor\u00aeSystem non-invasively rules out CAD with 97% negative predictive value. Following this, the CADScor\u00aeSystem has been commercially launched in the Nordics and Germany to both private and public cardiology centers.<\/p>\n

In addition to seeing demonstrations of the CADScor\u00aeSystem on booth F140 in the Emerging Technology Showcase Area, delegates will also be able to learn about study results from Principal Investigator Morten B\u00f6ttcher, MD PhD FESC and Simon Winther, MD PhD, Department of Cardiology, Herning Hospital, Denmark.<\/p>\n

Acarix CEO S\u00f8ren Rysholt Christiansen commented: "We are very pleased to be presenting CADScor\u00aeSystem in the Emerging Technology Showcase Area. Already CADScor\u00aeSystem is in clinical use and is generating interest in our initial German and Nordic target markets, and we now look forward to introducing it to a wider audience including European cardiologists and other experts attending ESC. CAD affects more than 120 million people worldwide but the current diagnostic pathway, which can rapidly escalate to imaging and coronary angiography can be significantly improved. The CADScor\u00aeSystem uses advanced acoustic technology to rapidly measure arterial flow in a non-invasive way and thus provide an accurate frontline assessment potentially leading to an improved triage. This will ensure patients in need of further diagnostic tests get them and that patients with symptoms unrelated to CAD do not."<\/em><\/p>\n

About the CADScor\u00aeSystem<\/strong><\/p>\n

The CADScor\u00aeSystem uses ultra-sensitive phonocardiography combined with advanced electronics and algorithms to rule out CAD with 97% negative predictive value. CADScor\u00aeSystem is fast, radiation-free, non- invasive and can be performed in every standard point-of-care environment in less than 10 minutes.<\/p>\n

In patients with suspected CAD, the current practice includes one or several examinations, i.e. stress tests, nuclear imaging, and invasive coronary angiography. In many cases, these patients are either healthy or end up not needing any treatment. The CADScor\u00aeSystem is designed to provide a first rapid and non-invasive, investigative step and by ruling out CAD earlier, the diagnostic pathway improves.<\/p>\n

Contacts:
<\/strong>Acarix
S\u00f8ren Rysholt Christiansen, CEO, E-mail: dksrc@acarix.com Phone: +45 2777 1112<\/p>\n

Notes to editors:
<\/strong>Acarix, CADScor\u00aeSystem and cardiac sound measurement
Acarix was established in 2009, and since 2010 investors SEED Capital (DK) and Sunstone Life Science Ventures (DK) have supported it towards market introduction. Acarix was listed on Nasdaq First North Premier in 2016 and has attracted a highly-experienced management team having held senior positions in international medical device companies – CEO S\u00f8ren Rysholt Christiansen with Cook Medical, GN ReSound, and ELOS Medtech.<\/p>\n

Acarix's CADScor\u00aeSystem is based on engineering excellence in sound recording and signal processing. It has long been known that both cardiac contraction movement and turbulent flow can generate sound. Contraction related sounds are in lower frequency, whereas turbulent sounds in the streaming blood caused by partial obstruction (stenosis) in the coronary arteries are of higher frequencies. The detection of these murmurs is delicate, since the energy of the murmurs is very weak. Detecting and recording the coronary murmurs requires not only an advanced sensor but also means for proper attachment to the skin above the heart to optimize the recorded signal and to avoid external noise.<\/p>\n

The Acarix CADScor\u00aeSystem has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen. The CADScor\u00aeSystem contains the necessary electronics to instruct professionals during use and to guide through the recording periods. The system also contains a docking station for daily qualification of the sensor. Further the system integrates with an adhesive patch for locking the sensor to a fixed position above the heart during the recording.<\/p>\n

See more at www.acarix.com. Press kit: http:\/\/www.acarix.com\/about-us\/press-downloads\/.<\/p>\n

20170823 Press release ESC_UK<\/a><\/p>\n

—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acarix AB via Globenewswire<\/em><\/p>\n

<\/div>\n